Hasil Pencarian  ::  Simpan CSV :: Kembali

"This book contains case studies of the discovery of erythromycin analogs (antibiotics), Tagamet, and Ultiva (remifentanil). Discusses the discovery of agents for the treatment and management of bacterial infections, Parkinson's disease, psoriasis, ulcers and stomach pain, atopic dermatitis, asthma, and cancer. Contains chapters on combinatorial chemistry, molecular biology-based drug discovery, genomics, and chemogenomics.The first volume of this set thoroughly describes conceptualizing a drug, creating a library of candidates for testing, screening those candidates for in vitro and in vivo activity, conducting and analyzing the results of clinical trials, and revising the drug as necessary."

"This book the only comprehensive guide of its kind, this groundbreaking two-volume resource provides an overview of the entire sequence of operations involved in drug discovery and development from initial conceptualization to commercialization to clinicians and medical practitioners.Volume 2 : drug development delves into the nitty-gritty details of optimizing the synthetic route, drug manufacturing, outsourcing, and marketing-including drug coloring and delivery methods.Featuring contributions from a world-class team of experts, Drug discovery and development :- Features fascinating case studies, including the discovery and development of erythromycin analogs, Tagamet, and Ultiva (remifentanil)- Discusses the discovery of medications for bacterial infections, Parkinson's disease, psoriasis, peptic ulcers, atopic dermatitis, asthma, and cancer- Includes chapters on combinatorial chemistry, molecular biology-based drug discovery, genomics, and chemogenomics"

"Molecular pathology offers tools and techniques that can greatly enhance the drug discovery and development process, helping to make the promises of personalized medicine a reality. Molecular Pathology in Drug Discovery and Development provides an unmatched guide to this cutting-edge discipline and its applications to pharmaceutical science.With contributions from leading lights in drug discovery, drug development, and molecular pathology balanced by a consistent editorial approach, this reference offers both an overview of molecular pathology and a close look at the methods as they are applied to the process of drug discovery and development. Presented as steps in the drug development process, the coverage includes the use of molecular pathology to :

• Identify and validate new drug candidates
• Enhance transcriptional profiling to better find and validate biomarkers
• Assess toxicology
• Employ toxicogenomics to identify genes relevant to the safety of compounds
• Identify correct doses for different drugs
• Identify patients for treatment
• Develop molecular therapies
• Further the new techniques of Immunohistochemistry and Immunofluorescence

With many tests and treatments already working today, drug research and development using molecular pathology has shown itself an extremely fruitful area. Molecular pathology in drug Discovery and development gives practitioners an up-to-date resource on this highly active discipline and its role in furthering pharmaceutical research."

"This book is the first systems biology text to focus on how systems biology can be specifically applied to enhance drug discovery and development, with particular emphasis on real-world examples. Other texts on systems biology to date have focused on particular subdisciplines of systems biology (such as cellular networks) and have not specifically addressed drug discovery and development. This book introduces key methodologies and technical approaches for helping to solve many of the current challenges facing the pharmaceutical and biotechnology industries."

""Computational biology drives discovery through its use of high-throughput informatics approaches. This book provides a road map of the current drug development process and how computational biology approaches play a critical role across the entire drug discovery pipeline. Through the use of previously unpublished, real-life case studies the impact of a range of computational approaches are discussed at various phases of the pipeline. Additionally, a focus section provides innovative visualisation approaches, from both the drug discovery process as well as from other fields that utilise large datasets, recognising the increasing use of such technology. Serving the needs of early career and more experienced scientists, this up-to-date reference provides an essential introduction to the process and background of drug discovery, highlighting how computational researchers can contribute to that pipeline"--Provided by publisher."

"This book covers the science and approaches of enzyme inhibition applied in drug discovery and drug development, including both pharmacology and pharmacokinetic aspects of enzyme inhibition. Additionally, the book covers the inhibition of drug metabolizing and disposition enzymes including transporters (mostly "bad" or "undesirable" enzyme inhibition) as well as the inhibition of drug target enzymes (mostly the "good" or "desirable" enzyme inhibition). Each chapter details the basic scientific concepts, experimental approaches, data interpretation, and current challenges and promising advancements for a specific type of inhibition."

"This handbook provides the first-ever inside view of today's integrated approach to rational drug design. Chemoinformatics experts from large pharmaceutical companies, as well as from chemoinformatics service providers and from academia demonstrate what can be achieved today by harnessing the power of computational methods for the drug discovery process. With the user rather than the developer of chemoinformatics software in mind, this book describes the successful application of computational tools to real-life problems and presents solution strategies to commonly encountered problems. It shows how almost every step of the drug discovery pipeline can be optimized and accelerated by using chemoinformatics tools-from the management of compound databases to targeted combinatorial synthesis, virtual screening and efficient hit-to-lead transition. "